Patents by Inventor William Joseph Hornback

William Joseph Hornback has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8178528
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: May 15, 2012
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Takako Takakuwa, Cynthia Darshini Jesudason, Robert Alan Gadski, William Joseph Hornback, Richard Todd Pickard, Lisa Selsam Beavers
  • Patent number: 8008296
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I).
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Patent number: 8008301
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Terry Patrick Finn, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Publication number: 20100160319
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: June 28, 2006
    Publication date: June 24, 2010
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Publication number: 20100160406
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: March 28, 2006
    Publication date: June 24, 2010
    Inventors: Philip Arthur Hipskind, Takako Takakuwa, Cynthia Darshini Jesudason, Robert Alan Gadski, William Joseph Hornback, Richard Todd Pickard, Lisa Selsman Beavers
  • Patent number: 7705025
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: April 27, 2010
    Assignee: Eli Lilly and Company
    Inventors: Don Richard Finley, Terry Patrick Finn, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Takako Takakuwa
  • Patent number: 7666871
    Abstract: The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: February 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Serge Louis Boulet, Terry Patrick Finn, Robert Alan Gadski, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Freddie Craig Stevens, Grant Mathews Vaught
  • Publication number: 20100029608
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-113 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: October 13, 2009
    Publication date: February 4, 2010
    Inventors: Don Richard FINLEY, Terry Patrick FINN, Philip Arthur HIPSKIND, William Joseph HORNBACK, Cynthia Darshini Jesudason, Takako TAKAKUWA
  • Patent number: 7642361
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: January 5, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano, Maria Carmen Fernandez, William Joseph Hornback, Alma Maria Jimenez-Aguado, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 7632857
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: December 15, 2009
    Assignee: Eli Lilly and Company
    Inventors: William Joseph Hornback, Cynthia Darshini Jesudason, Grant Mathews Vaught
  • Patent number: 7625932
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: December 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang, Paul Leslie Ornstein, Michelle Lee Thompson, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Ana Maria Castano Mansanet, Larry Gene Huffman, William David Miller
  • Publication number: 20090048225
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: August 15, 2005
    Publication date: February 19, 2009
    Inventors: Don Richard Finley, Terry Patrick Finn, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Takako Takakuwa
  • Patent number: 7393868
    Abstract: The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: July 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Frederic Laurent Cordier, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang
  • Patent number: 7173107
    Abstract: The stereospecific synthesis of a glycopeptide using a triply orthogonal protection scheme is described, in particular, the synthesis of N-acetylglucosaminyl-?-[1,4]-N-acetylmuramylmonopeptide and derivatives thereof. The glycopeptide is useful for the preparation of GMDP and related compounds having a glucosaminyl-?-[1,4]-N-acetylmuramic acid disaccharide core.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: February 6, 2007
    Assignee: Eli Lilly and Company
    Inventors: Larry Chris Blaszczak, Elizabeth Anne Dingess-Hammond, William Joseph Hornback, Michael Scott VanNieuwenhze
  • Publication number: 20040006114
    Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
    Type: Application
    Filed: November 20, 2002
    Publication date: January 8, 2004
    Inventors: Darrell Stephen Coleman, Gunnar Erik Jagdmann, Kirk Willis Johnson, Michael Parvin Johnson, Thomas Hallett Large, James Allen Monn, Darryle Darwin Schoepp, David Anthony Barda, Thomas Charles Britton, Bruce Anthony Dressman, Steven Scott Henry, William Joseph Hornback, Joseph Patrick Tizzano, Michael William Fichtner
  • Publication number: 20030187186
    Abstract: The stereospecific synthesis of a glycopeptide using a triply orthogonal protection scheme is described, in particular, the synthesis of N-acetylglucosaminyl-&bgr;-[1,4]-N-acetylmuramylmonopeptide and derivatives thereof. The glycopeptide is useful for the preparation of GMDP and related compounds having a glucosaminyl-&bgr;-[1,4]-N-acetylmuramic acid disaccharide core.
    Type: Application
    Filed: October 3, 2002
    Publication date: October 2, 2003
    Inventors: Larry Chris Blaszczak, Elizabeth Anne Dingess-Hammond, William Joseph Hornback, Michael Scott VanNieuwenzhe
  • Patent number: 6037348
    Abstract: The present invention provides a method of inhibiting influenza and flaviviral replication based on a mechanism of action in which HA-mediated fusion or E protein mediated fusion is inhibited by a fusion inhibiting agent which binds, complexes or otherwise becomes associated with HA or E protein during the translation of the target protein and/or its vesicular transport.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: March 14, 2000
    Assignee: Eli Lilly and Company
    Inventors: Joseph Matthew Colacino, Steven Duane Hatch, William Joseph Hornback, Mark Ayer Muesing, John Edwin Munroe, Kirk Alan Staschke, Joseph Chiou-Chung Tang